Ascendiant Capital Markets Cuts Aemetis (NASDAQ:AMTX) Price Target to $19.00

Aemetis (NASDAQ:AMTX) had its price objective lowered by Ascendiant Capital Markets from $20.00 to $19.00 in a research note released on Tuesday morning, MarketBeat reports. The firm currently has a buy rating on the specialty chemicals company’s stock.

Several other equities analysts have also recently commented on the stock. HC Wainwright reissued a buy rating and issued a $28.00 price target on shares of Aemetis in a research report on Friday, August 2nd. UBS Group dropped their price target on shares of Aemetis from $8.25 to $7.75 and set a buy rating on the stock in a research note on Monday, August 19th. StockNews.com upgraded Aemetis to a sell rating in a research report on Wednesday, July 31st. Finally, Truist Financial reaffirmed a hold rating and issued a $3.50 target price (down from $4.00) on shares of Aemetis in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Aemetis currently has a consensus rating of Moderate Buy and an average target price of $12.95.

Aemetis Price Performance

NASDAQ AMTX opened at $2.21 on Tuesday. The stock has a market capitalization of $98.12 million, a P/E ratio of -1.89 and a beta of 1.31. The firm’s 50-day moving average is $2.93 and its two-hundred day moving average is $3.53. Aemetis has a 12 month low of $2.10 and a 12 month high of $7.03.

Aemetis (NASDAQ:AMTX) last posted its earnings results on Thursday, August 1st. The specialty chemicals company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The company had revenue of $66.56 million for the quarter, compared to analysts’ expectations of $75.37 million. During the same period in the previous year, the business earned ($0.68) EPS. As a group, analysts anticipate that Aemetis will post -2.19 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AMTX. Bank of New York Mellon Corp acquired a new stake in Aemetis in the second quarter valued at about $306,000. Susquehanna Fundamental Investments LLC raised its stake in shares of Aemetis by 287.4% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock worth $379,000 after buying an additional 93,536 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares during the period. Hutchinson Capital Management CA purchased a new stake in shares of Aemetis in the second quarter valued at approximately $70,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Aemetis in the first quarter valued at approximately $84,000. 27.02% of the stock is currently owned by institutional investors and hedge funds.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.